<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">Abeona Therapeutics</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:25b55a8f-6e58-4f96-ad54-d0e9c381db6f;id=7192</id> <rights type="text">Copyright 2017, Abeona Therapeutics</rights> <updated>2017-01-03T12:43:00Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/Y_AD6goL3D7uC6COVw7W9g==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/Y_AD6goL3D7uC6COVw7W9g==" /> <entry> <id>https://www.globenewswire.com/news-release/2017/01/03/983383/0/en/Abeona-Therapeutics-Receives-Orphan-Drug-Designation-in-The-European-Union-for-ABO-201-Gene-Therapy-Program-in-Juvenile-Batten-Disease.html</id> <title type="text">Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-201 Gene Therapy Program in Juvenile Batten Disease</title> <published>2017-01-03T12:43:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/01/03/983383/0/en/Abeona-Therapeutics-Receives-Orphan-Drug-Designation-in-The-European-Union-for-ABO-201-Gene-Therapy-Program-in-Juvenile-Batten-Disease.html" /> <content type="html"><![CDATA[<p> </p>]]></content> <dc:identifier>983383</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/12/06/983382/0/en/Abeona-Therapeutics-to-Present-at-2016-Genetic-Rx-Boston-Biotech-Conference-at-Harvard-Medical-School.html</id> <title type="text">Abeona Therapeutics to Present at 2016 Genetic Rx Boston Biotech Conference at Harvard Medical School</title> <published>2016-12-06T12:43:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/12/06/983382/0/en/Abeona-Therapeutics-to-Present-at-2016-Genetic-Rx-Boston-Biotech-Conference-at-Harvard-Medical-School.html" /> <content type="html"><![CDATA[<p align="left"> <span class="mw_region">NEW YORK, NY and CLEVELAND, OH</span><span>--(Marketwired - December 06, 2016) - </span><strong> </strong>Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced President and CEO, Timothy J. Miller, Ph.D., will participate in a panel discussion at the 2016 Genetic Rx Conference at the Harvard Medical School in Boston, MA.</p>]]></content> <dc:identifier>983382</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/11/15/983381/0/en/Abeona-Therapeutics-to-Present-at-World-Orphan-and-Drug-Congress-Europe-2016.html</id> <title type="text">Abeona Therapeutics to Present at World Orphan and Drug Congress Europe 2016</title> <published>2016-11-15T12:58:06Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/11/15/983381/0/en/Abeona-Therapeutics-to-Present-at-World-Orphan-and-Drug-Congress-Europe-2016.html" /> <content type="html"><![CDATA[<p><em><p>Company CEO and VP of Patient Advocacy to Present on Wednesday, November 16 at 11:30 am & 17:00 pm CET </p></em></p><p> <span class="mw_region">NEW YORK, NY and CLEVELAND, OH</span><span>--(Marketwired - November 15, 2016) - </span>Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO & President, Timothy J. Miller, PhD, presenting and VP of Patient Advocacy, Michelle Berg, moderating a panel discussion for the Company at the World Orphan and Drug Congress Europe 2016.</p>]]></content> <dc:identifier>983381</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/11/10/983380/0/en/Abeona-Therapeutics-Announces-Third-Quarter-2016-Financial-Results-and-Recent-Clinical-Highlights.html</id> <title type="text">Abeona Therapeutics Announces Third Quarter 2016 Financial Results and Recent Clinical Highlights</title> <published>2016-11-10T12:43:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/11/10/983380/0/en/Abeona-Therapeutics-Announces-Third-Quarter-2016-Financial-Results-and-Recent-Clinical-Highlights.html" /> <content type="html"><![CDATA[<p><em><p>Investor Conference Call to be held Friday, November 18 at 10:30 am ET</p></em></p><p> <span class="mw_region">NEW YORK, NY and CLEVELAND, OH</span><span>--(Marketwired - November 10, 2016) - </span> Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced financial results for the third quarter. The Company will provide investors an update on recent and ongoing business activities and an overview of its 3Q16 financials on, Friday, November 18 at 10:30 am (Eastern). Interested parties are invited to participate in the call by dialing 877-269-7756 (toll free domestic) or 201-689-7817 (international).</p>]]></content> <dc:identifier>983380</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/11/05/983379/0/en/Abeona-Therapeutics-Honored-with-Partner-in-Progress-Award-from-DEBRA-of-America.html</id> <title type="text">Abeona Therapeutics Honored with Partner in Progress Award from DEBRA of America</title> <published>2016-11-05T18:03:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/11/05/983379/0/en/Abeona-Therapeutics-Honored-with-Partner-in-Progress-Award-from-DEBRA-of-America.html" /> <content type="html"><![CDATA[<p><em><p>Recognized for Developing Potential Therapies for Rare Genetic Disorder, Epidermolysis Bullosa </p></em></p><p> <span class="mw_region">NEW YORK, NY and CLEVELAND, OH</span><span>--(Marketwired - November 05, 2016) - </span>Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced the Company was honored with a Partners in Progress Award from the Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA). The award recognizes the company's work developing therapies for patients suffering with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of epidermolysis bullosa (EB), a devastating life-threatening genetic skin disorder impacting children for which there is currently no cure.</p>]]></content> <dc:identifier>983379</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/11/03/983378/0/en/Abeona-Therapeutics-to-Present-at-Alliance-of-Regenerative-Medicine-4th-Annual-Advanced-Therapies-Investor-Day-in-London-UK.html</id> <title type="text">Abeona Therapeutics to Present at Alliance of Regenerative Medicine 4th Annual Advanced Therapies Investor Day in London, UK</title> <published>2016-11-03T11:43:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/11/03/983378/0/en/Abeona-Therapeutics-to-Present-at-Alliance-of-Regenerative-Medicine-4th-Annual-Advanced-Therapies-Investor-Day-in-London-UK.html" /> <content type="html"><![CDATA[<p><em><p>Company CEO to Present on Thursday, November 3rd at 1:30 pm UTC</p></em></p><p> <span class="mw_region">NEW YORK, NY and CLEVELAND, OH</span><span>--(Marketwired - November 03, 2016) - </span> Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO & President, Timothy J. Miller, Ph.D. will be presenting, and joining the Clinical Progress of Gene Therapy Panel, at the Alliance of Regenerative Medicine (ARM) 4<sup>th</sup> Annual Advanced Therapies Investor Day in London, UK.</p>]]></content> <dc:identifier>983378</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/11/02/983377/0/en/Abeona-Therapeutics-Announces-JAMA-Publication-of-Positive-Phase-1-Study-Results-for-EB-101-Gene-Therapy-Clinical-Trial-for-Epidermolysis-Bullosa.html</id> <title type="text">Abeona Therapeutics Announces JAMA Publication of Positive Phase 1 Study Results for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa</title> <published>2016-11-02T12:03:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/11/02/983377/0/en/Abeona-Therapeutics-Announces-JAMA-Publication-of-Positive-Phase-1-Study-Results-for-EB-101-Gene-Therapy-Clinical-Trial-for-Epidermolysis-Bullosa.html" /> <content type="html"><![CDATA[<p align="left"> <span class="mw_region">NEW YORK, NY and CLEVELAND, OH</span><span>--(Marketwired - November 02, 2016) - </span>Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>):</p>]]></content> <dc:identifier>983377</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/11/01/983376/0/en/Abeona-Therapeutics-Inc-Announces-Closing-of-its-Underwritten-Offering-of-Common-Stock.html</id> <title type="text">Abeona Therapeutics Inc. Announces Closing of its Underwritten Offering of Common Stock</title> <published>2016-11-01T14:23:31Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/11/01/983376/0/en/Abeona-Therapeutics-Inc-Announces-Closing-of-its-Underwritten-Offering-of-Common-Stock.html" /> <content type="html"><![CDATA[<p align="left"> <span class="mw_region">NEW YORK, NY, and CLEVELAND, OH</span><span>--(Marketwired - November 01, 2016) - </span>Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>), a clinical stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced the closing of its underwritten public offering of 6,000,000 shares of common stock, at a public offering price of $7.00 per share. The gross offering size was approximately $42,000,000 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company.</p>]]></content> <dc:identifier>983376</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/10/27/983374/0/en/Abeona-Therapeutics-Announces-Pricing-of-Public-Offering-of-Common-Stock.html</id> <title type="text">Abeona Therapeutics Announces Pricing of Public Offering of Common Stock</title> <published>2016-10-27T13:12:01Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/10/27/983374/0/en/Abeona-Therapeutics-Announces-Pricing-of-Public-Offering-of-Common-Stock.html" /> <content type="html"><![CDATA[<p align="left"> <span class="mw_region">NEW YORK, NY, and CLEVELAND, OH</span><span>--(Marketwired - October 27, 2016) - </span>Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>), a clinical stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced the pricing of an underwritten public offering of 6,000,000 shares of common stock at a public offering price of $7.00 per share. The gross offering size for this offering is expected to be approximately $42,000,000 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 900,000 shares of common stock. The offering is expected to close on or about November 1, 2016, subject to customary closing conditions.</p>]]></content> <dc:identifier>983374</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/10/26/983373/0/en/Abeona-Therapeutics-Announces-Public-Offering-of-Common-Stock.html</id> <title type="text">Abeona Therapeutics Announces Public Offering of Common Stock</title> <published>2016-10-26T20:14:18Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/10/26/983373/0/en/Abeona-Therapeutics-Announces-Public-Offering-of-Common-Stock.html" /> <content type="html"><![CDATA[<p align="left"> <span class="mw_region">NEW YORK, NY, and CLEVELAND, OH</span><span>--(Marketwired - October 26, 2016) - </span><strong> </strong>Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>), a clinical stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement. All of the shares in the offering are to be sold by Abeona. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p>]]></content> <dc:identifier>983373</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/10/25/983372/0/en/Abeona-Therapeutics-Announces-Fast-Track-Designation-from-FDA-for-ABO-102-in-Sanfilippo-Syndrome-Type-A.html</id> <title type="text">Abeona Therapeutics Announces Fast Track Designation from FDA for ABO-102 in Sanfilippo Syndrome Type A</title> <published>2016-10-25T11:45:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/10/25/983372/0/en/Abeona-Therapeutics-Announces-Fast-Track-Designation-from-FDA-for-ABO-102-in-Sanfilippo-Syndrome-Type-A.html" /> <content type="html"><![CDATA[<p><em><p>Fast Track Designation Added to Already Granted Orphan Drug Designation by the FDA and European Medicines Agency (EMA), and Rare Pediatric Disease Designation for ABO-102 in Sanfilippo Syndrome Type A (MPS IIIA)</p></em></p><p align="left"> <span class="mw_region">NEW YORK, NY and CLEVELAND, OH</span><span>--(Marketwired - October 25, 2016) - </span> Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for ABO-102, a single intravenous injection of AAV gene therapy for subjects with MPS IIIA (Sanfilippo syndrome type A), a rare autosomal recessive disease affecting every cell and organ in the body causing neurocognitive decline, speech loss, loss of mobility, and premature death in children.</p>]]></content> <dc:identifier>983372</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/10/20/983371/0/en/Abeona-Therapeutics-Provides-Update-from-ABO-102-Phase-1-2-MPS-IIIA-Clinical-Trial-at-Orphan-Drugs-Rare-Disease-Conference-London-UK.html</id> <title type="text">Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at Orphan Drugs & Rare Disease Conference, London UK</title> <published>2016-10-20T11:43:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/10/20/983371/0/en/Abeona-Therapeutics-Provides-Update-from-ABO-102-Phase-1-2-MPS-IIIA-Clinical-Trial-at-Orphan-Drugs-Rare-Disease-Conference-London-UK.html" /> <content type="html"><![CDATA[<p> <span class="mw_region">NEW YORK, NY and CLEVELAND, OH</span><span>--(Marketwired - October 20, 2016) - </span> Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>):</p>]]></content> <dc:identifier>983371</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/10/18/983368/0/en/Abeona-Therapeutics-Receives-Orphan-Drug-Designation-in-The-European-Union-for-ABO-102-Gene-Therapy-in-Sanfilippo-Syndrome-Type-A.html</id> <title type="text">Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-102 Gene Therapy in Sanfilippo Syndrome Type A</title> <published>2016-10-18T11:45:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/10/18/983368/0/en/Abeona-Therapeutics-Receives-Orphan-Drug-Designation-in-The-European-Union-for-ABO-102-Gene-Therapy-in-Sanfilippo-Syndrome-Type-A.html" /> <content type="html"><![CDATA[<p align="center" style="text-align:left"><span class="mw_region">NEW YORK, NY, and CLEVELAND, OH</span><span>--(Marketwired - October 18, 2016) - </span>Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>), a clinical- stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation for Abeona's lead gene therapy program ABO-102 for the treatment of patients with Sanfilippo syndrome type A (MPS IIIA), a rare autosomal recessive disease that causes neurocognitive decline, speech loss, loss of mobility, and premature death in children.</p>]]></content> <dc:identifier>983368</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/10/14/983366/0/en/Abeona-Therapeutics-to-Present-Top-Line-Data-of-Low-Dose-Cohort-for-ABO-102-in-Phase-1-2-Clinical-Trial-for-MPS-IIIA-Patients-at-Upcoming-Orphan-Drugs-and-Rare-Disease-Congress-Oct.html</id> <title type="text">Abeona Therapeutics to Present Top-Line Data of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients at Upcoming Orphan Drugs and Rare Disease Congress October 19-20th in London, UK</title> <published>2016-10-14T11:03:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/10/14/983366/0/en/Abeona-Therapeutics-to-Present-Top-Line-Data-of-Low-Dose-Cohort-for-ABO-102-in-Phase-1-2-Clinical-Trial-for-MPS-IIIA-Patients-at-Upcoming-Orphan-Drugs-and-Rare-Disease-Congress-Oct.html" /> <content type="html"><![CDATA[<p><em><p>Conference Call to Update Investors on ABO-102 Program During the Conference</p></em></p><p> <span class="mw_region">NEW YORK, NY and CLEVELAND, OH</span><span>--(Marketwired - October 14, 2016) - </span>Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>), a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that top-line results of the low-dose cohort for ABO-102 in Phase 1/2 clinical trial for Sanfilippo type A (MPS IIIA) patients will be presented at the Orphan Drugs and Rare Disease Congress taking place in London, UK, from October 19<sup>th</sup> through October 20<sup>th</sup>. The company's ABO-102 program, enrolling at Nationwide Children's Hospital (Columbus, Ohio), is the first-in-man clinical trial utilizing a single intravenous injection of AAV gene therapy for MPS IIIA, a rare autosomal recessive disease that causes neurocognitive decline, speech loss, loss of mobility, and premature death in children. Abeona management will provide an update on the ABO-102 and other programs on a conference call during the conference.</p>]]></content> <dc:identifier>983366</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/10/07/983364/0/en/Abeona-Therapeutics-Announces-Publication-of-Preclinical-Data-Supporting-Clinical-Translation-of-Juvenile-Batten-Disease-Gene-Therapy.html</id> <title type="text">Abeona Therapeutics Announces Publication of Preclinical Data Supporting Clinical Translation of Juvenile Batten Disease Gene Therapy</title> <published>2016-10-07T13:19:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/10/07/983364/0/en/Abeona-Therapeutics-Announces-Publication-of-Preclinical-Data-Supporting-Clinical-Translation-of-Juvenile-Batten-Disease-Gene-Therapy.html" /> <content type="html"><![CDATA[<p> <span class="mw_region">NEW YORK, NY and CLEVELAND, OH</span><span>--(Marketwired - October 07, 2016) - </span> Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>):</p>]]></content> <dc:identifier>983364</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/10/05/983362/0/en/Abeona-Therapeutics-Announces-Data-Safety-Monitoring-Board-Approves-ABO-102-Dose-Escalation-for-Second-Cohort-in-Phase-1-2-Clinical-Trial-for-Sanfilippo-Syndrome-Type-A.html</id> <title type="text">Abeona Therapeutics Announces Data Safety Monitoring Board Approves ABO-102 Dose Escalation for Second Cohort in Phase 1/2 Clinical Trial for Sanfilippo Syndrome Type A</title> <published>2016-10-05T11:03:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/10/05/983362/0/en/Abeona-Therapeutics-Announces-Data-Safety-Monitoring-Board-Approves-ABO-102-Dose-Escalation-for-Second-Cohort-in-Phase-1-2-Clinical-Trial-for-Sanfilippo-Syndrome-Type-A.html" /> <content type="html"><![CDATA[<p> <span class="mw_region">NEW YORK, NY and CLEVELAND, OH</span><span>--(Marketwired - October 05, 2016) - </span> Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>)</p>]]></content> <dc:identifier>983362</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/10/04/983361/0/en/Abeona-Therapeutics-to-Present-at-Jefferies-Gene-Editing-Gene-Therapy-Summit.html</id> <title type="text">Abeona Therapeutics to Present at Jefferies Gene Editing & Gene Therapy Summit</title> <published>2016-10-04T11:03:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/10/04/983361/0/en/Abeona-Therapeutics-to-Present-at-Jefferies-Gene-Editing-Gene-Therapy-Summit.html" /> <content type="html"><![CDATA[<p><em><p>Company CEO to Present on Tuesday, October 11th at 11 am ET</p></em></p><p> <span class="mw_region">NEW YORK, NY and CLEVELAND, OH </span><span>--(Marketwired - October 04, 2016) - </span>Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO & President, Timothy J. Miller, Ph.D., will be presenting for The Company at Jefferies Gene Editing & Gene Therapy Summit, October 11<sup>th </sup>at 11 am ET in New York City.</p>]]></content> <dc:identifier>983361</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/09/29/983359/0/en/Abeona-Therapeutics-to-Present-at-Cell-Gene-Meeting-on-the-Mesa.html</id> <title type="text">Abeona Therapeutics to Present at Cell Gene Meeting on the Mesa</title> <published>2016-09-29T11:03:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/09/29/983359/0/en/Abeona-Therapeutics-to-Present-at-Cell-Gene-Meeting-on-the-Mesa.html" /> <content type="html"><![CDATA[<p><em><p>Company CEO to Present on October 5th at 11:15 am PT</p></em></p><p> <span class="mw_region">NEW YORK, NY and CLEVELAND, OH</span><span>--(Marketwired - September 29, 2016) - </span>Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO & President, Timothy J. Miller, Ph.D., will be presenting for The Company at Cell Gene's Meeting on the Mesa in La Jolla, CA , October 5<sup>th</sup> at 11:15 am PT.</p>]]></content> <dc:identifier>983359</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/09/26/983356/0/en/Abeona-Therapeutics-Enrolls-First-Patient-in-Phase-2-for-EB-101-Gene-Therapy-Clinical-Trial-for-Epidermolysis-Bullosa.html</id> <title type="text">Abeona Therapeutics Enrolls First Patient in Phase 2 for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa</title> <published>2016-09-26T11:03:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/09/26/983356/0/en/Abeona-Therapeutics-Enrolls-First-Patient-in-Phase-2-for-EB-101-Gene-Therapy-Clinical-Trial-for-Epidermolysis-Bullosa.html" /> <content type="html"><![CDATA[<p align="left"> <span class="mw_region">NEW YORK, NY and CLEVELAND, OH</span><span>--(Marketwired - September 26, 2016) - </span>Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>)</p>]]></content> <dc:identifier>983356</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/09/23/983354/0/en/Abeona-Therapeutics-to-Present-at-Ladenburg-Thalmann-2016-Healthcare-Conference.html</id> <title type="text">Abeona Therapeutics to Present at Ladenburg Thalmann 2016 Healthcare Conference</title> <published>2016-09-23T11:03:00Z</published> <updated>2024-11-22T18:03:49Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/09/23/983354/0/en/Abeona-Therapeutics-to-Present-at-Ladenburg-Thalmann-2016-Healthcare-Conference.html" /> <content type="html"><![CDATA[<p><em><p>Company COO to Present on September 27th at 9:30 am ET</p></em></p><p align="left"> <span class="mw_region">NEW YORK, NY and CLEVELAND, OH</span><span>--(Marketwired - September 23, 2016) - </span><strong> </strong>Abeona Therapeutics Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ABEO">ABEO</ticker>) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that COO Jeffrey Davis, will be presenting for The Company at The Ladenburg Thalmann 2016 Healthcare Conference in New York City, September 27<sup>th </sup>at 9:30 am ET.</p>]]></content> <dc:identifier>983354</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Abeona Therapeutics Inc.</dc:contributor> <dc:modified>Wed, 20 Sep 2017 01:47 GMT</dc:modified> </entry> </feed>